Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic Study
Preprint
Abstract
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease, and when. In this longitudinal Olink Explore high-throughput proteomic study, 516 serially collected plasma samples from 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls were included. We identified 81 proteins whose concentrations changed prior to phenoconversion; characterized the longitudinal trajectory of these proteins; and identified a core panel of 19 proteins that, collectively, predicted phenoconversion over the 0.5- to 5-year time horizons (areas under curve 0.80-0.89) and yielded estimates of time-to-phenoconversion with a mean absolute error of 1.6 years. These findings were replicated in UK Biobank data, confirming pre-symptomatic increases in several proteins (e.g. NEFL, EDA2R, CA3) and that a multi-protein panel outperformed NEFL alone in estimating time-to-phenoconversion. This work sheds light on the biology of pre-symptomatic ALS. Moreover, our identification of a panel of novel susceptibility/risk biomarkers based on empirical longitudinal data furthers the ultimate goal of ALS prevention.Keywords
This publication has 42 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Ectodysplasin A2 receptor signaling in skeletal muscle pathophysiologyTrends in Molecular Medicine, 2024
- Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyNeurotherapeutics, 2022
- Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide AnalysisMolecular & Cellular Proteomics, 2021
- Megf10 deficiency impairs skeletal muscle stem cell migration and muscle regenerationFEBS Open Bio, 2020
- Sarcolemmal loss of active nNOS (Nos1) is an oxidative stress‐dependent, early event driving disuse atrophyThe Journal of Pathology, 2018
- Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversionAnnals of Neurology, 2018
- The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelAlzheimer's & Dementia, 2016
- ALS biomarkers for therapy development: State of the field and future directionsMuscle & Nerve, 2015
- Calcitonin gene-related peptide expression levels predict motor neuron vulnerability in the superoxide dismutase 1-G93A mouse model of amyotrophic lateral sclerosisNeurobiology of Disease, 2012